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Abstract 
Objective
The Tight Control of Psoriatic arthritis (TICOPA, ISCRCTN30147736) trial, compared 
standard care (StdC) and tight control (TC) in early PsA, demonstrating better 
outcomes for TC. This sub-study evaluated the performance metrics of modern 
imaging outcomes and compared them to the clinical data.
Methods
Non-contrast 0.2TMRI (single hand) was assessed using the OMERACT PsAMRIS 
with an additional global inflammation score. Ultrasound (US, same hand) was 
scored for grey scale, power Doppler and erosions at the metacarpophalangeal 
(MCP) and proximal interphalangeal (PIP) joints and scores summated. 
Results
78 patients had paired (baseline and 48 weeks) US data and 63 paired MRI data; 50 
had matched clinical, MR and US data. Significant within-group changes were seen 
for the inflammatory PsAMRIS components at MCP level: MRI global inflammation 
(Median difference (range), Standardised Response Mean, SRM): 3.25 (- 5.0 – 12.0) 
0.68, 1.0 (-4.5 – 17.5), 0.45 for TC and StdC respectively. Similar within group 
differences were obtained for US: 1.0 (-13.0 – 23.0), 0.45, 3.0 (-6.0 – 21.0), 0.77 for 
TC and StdC respectively. No differences were seen between treatment groups. 
Significant correlations were found between baseline and change MRI and US 
scores. A significant correlation was found between baseline PsA disease activity 
scores and MRI global inflammation scores (Spearman’s rho for MCP, PIP 0.46, 
0.63 respectively). No differences in erosion progression were observed.
Conclusion
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The PsAMRIS and US inflammation scores demonstrated good responsiveness. No 
between group differences were demonstrated but this sub-study was likely under-
powered to determine differences between the two treatment strategies.
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Introduction
The emphasis placed on treating inflammatory arthritis as early as possible to 
minimise damage and functional disability has been shown to be effective in 
rheumatoid arthritis (RA)[1] and the concept has been extended to other 
inflammatory arthritides such as psoriatic arthritis (PsA). The Tight Control of 
inflammation in Psoriatic arthritis (TICOPA) trial targeted early, treatment naïve 
patients and demonstrated improved clinical outcomes above usual care, but was 
unable to demonstrate an advantage in terms of radiographic progression in hands 
and feet [2]. 
Modern imaging modalities such as magnetic resonance imaging (MRI) or 
ultrasound (US) provide sensitive tools to explore both objective inflammation and 
damage responses, though there are extremely few PsA studies using these 
modalities [3].  It is also unclear, given the known patterns of PsA joint involvement, 
whether imaging a single hand (as is typically done in RA trials using MRI) will 
provide a responsive tool. 
The aim of this study was therefore to describe and compare the performance 
metrics of commonly-used MRI and US scores in an imaging sub-study of the 
TICOPA study, and to compare these imaging outcomes with the clinical data 
obtained in this randomised trial.
Patients and Methods
The full trial protocol and clinical results of the TICOPA study have been previously 
reported (ISCRCTN30147736) [2, 4]. In brief this randomised, controlled, parallel 
group, open label, multi-centre clinical trial recruited people with early (less than 2 
years), treatment naive PsA. The trial had ethical approval from North East York 
Ethics Committee (14/NE/1090) and all participants gave written informed consent.  
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The primary objective of the main trial was to compare tight control (TC) with 
standard care (StdC), using minimal disease activity (MDA[5]) as the treatment 
target. Participants received either TC or StdC for a period of 48 weeks. Participants 
randomised to TC were seen every 4 weeks by the study physician and treated 
according to a predefined treatment protocol.  Participants randomised to the StdC 
arm were treated in a general rheumatology outpatient clinic supervised by a 
consultant rheumatologist.  These patients were generally reviewed every 12 weeks 
but were seen more often if clinically indicated, with no formal measures of disease 
activity used in clinical decision making. A blinded assessor collected clinical 
assessments and patient reported outcomes every 12 weeks. Disease activity was 
measured using the Psoriatic arthritis Disease Activity Score (PASDAS) which 
assesses patient and physician global assessment of disease, tender and swollen 
joint counts, dactylitis and enthesitis, CRP and the physical summary subscale of the 
short form 36 health related quality of life [6]. 
Magnetic Resonance Imaging
At the Leeds site, consenting patients were invited to participate in both MRI and US 
sub-studies, imaging the hand (the most affected hand, or the dominant hand if both 
were asymptomatic). Imaging was performed with both a non-contrast low field 
extremity MRI (0.2T C-scan, Esaote, Genova, Italy) and an US scan at baseline and 
48 weeks. 
MRI imaging
For the MRI scan the imaging sequences and details of scoring are as follow:
Scout. Whole hand FOV 140*140 TR 140ms. Matrix 192*128
STIR coronal. TR 2620ms. 160*160 matrix 192*144. 3 slices. 24 echoes.
STIR sagittal. TR 2840ms. 190*190. 192*144. 4 slices. 25 echoes.
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T1 3D coronal. T3D T1. TR 35ms. 140*140 80 matrix 192*160 72. 2 slices 88 
echoes. 
Images were scored for the second to fifth fingers at each level in the hand 
(metacarpophalangeal joint, proximal interphalangeal joint, distal interphalangeal joint) 
for the following features based on the OMERACT PsAMRIS score [7].:
Synovitis: Grading scale: 0 is normal, while 1–3 is mild, moderate, severe, by thirds 
of the maximum potential volume of tissue. Score range at each level for eachfinger, 
0 – 36.
Tenosynovitis: Grading scale: the maximal thickness of  signal as follows: 0:
none; 1: < 1/2 tendon thickness; 2: ≥ 1/2 and < 1 tendon
thickness; 3: ≥ 1 tendon thickness. Score range at each level for each finger, 0 – 36.
Periarticular inflammation (distal and proximal):  Grading scale, 0 absent, 1 present 
on both dorsal and volar aspects. Score range at each level for each finger, 0 – 24.
Bone edema (distal and proximal):  Grading scale: the scale is based on the 
proportion of bone with edema, compared to the assessed bone volume, judged 
on all available images: 0: no edema; 1: 1–33% of bone edematous; 2: 34–66%; 3:
67–100% scored on either side of the joint. Score range at each level for each finger, 
0 – 72.
Scores for synovitis, tenosynovitis, peri-articular inflammation and bone oedema 
were summed to give a ‘global inflammation’ score at each level, for each finger, 
score range 0 – 168. The aggregate scores at each level were retained in order to 
examine the responsiveness of ‘global inflammation’ in very small joints such as the 
DIPJ, and to determine which joints demonstrated most change with respect to this 
feature.
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Bone erosion (distal and proximal): Grading scale: the scale is 0–10, based on the 
proportion of eroded bone compared to the assessed bone volume, judged on 
all available images: 0:no erosion; 1: 1–10% of bone eroded; 2: 11–20%, and so on. 
Scored at either side of the joint. Score range at each level for all 4 fingers 0 – 240.
Bone proliferation: Grading scale: 0 absent, 1 present. Score range at each level for 
all 4 fingers 0 – 12.
 The images were read by two independent readers (NC, GL), anonymized to patient 
demographics, treatment group and time order. Inter-rater reliability for domain 
scores at each joint level was calculated by intra-class correlation coefficients.
Ultrasound imaging 
One of two ultrasonographers (JF and JN) scanned the same hand as the MRI using 
a Philips HDI 5000 (Best, The Netherlands) machine employing 12-5 and 15-7 MHz 
linear transducers and were unaware of the clinical examination findings. The inter-
rater agreement between these assessors for this group of patients has been 
previously reported [8].   PD was assessed using a pulse repetition frequency of 750 
Hz and medium wall filter and gain was adjusted until background signal was 
removed.  Each joint was scanned in both longitudinal and transverse planes from 
the dorsal aspect. For the small joints of the hand the second to fifth 
metacarpophalangeal (MCP) joints, and the second to fifth proximal inter-phalangeal 
(PIP) joints were examined. GS and PD were scored separately on a 0-3 semi-
quantitative scale for each joint imaged.  A GS score of ≥2 and/or a PD score ≥1 
were used to identify US active joints. The GS and PD scores were summated to 
give an overall score for ‘inflammation’ (total possible score of 48) [9]. Erosions were 
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defined as a definite cortical break seen in two planes and scored as present or 
absent at the joint level, so the maximum score for erosions per hand was 8. 
Statistical analysis
The original TICOPA study was appropriately powered for its clinical outcome, but no 
formal power calculation was made for this sub-study. Only matched (baseline and 
follow up) MRI and US data, and combined MRI, US and clinical data were used. 
There was no data imputation. The clinical composite outcome (the Psoriatic arthritis 
Disease Activity Index, PASDAS), was derived as previously described [6]. 
Significance was assumed at a level of 5%; no correction was made for multiple 
comparisons. Inter-rater reliability for aggregate MR scores was assessed using the 
intra-class correlation coefficient. The magnitude of MR parameter response was 
compared using the standardised response mean (SRM), calculated as the mean 
difference between time points divided by the standard deviation of the difference 
[10]. Statistical testing was carried out using SPSS v21.
Results
In the TICOPA study 206 patients were recruited and of these 85 entered imaging 
sub-studies. Clinical characteristics of the patients in this study were: Male/Female 
40/45; mean age 45.1 years; mean tender joint count 11.7; mean swollen joint count 
7.3; mean skin score (Psoriasis Area and Severity Score: PASI) 2.7; mean CRP 
(mg/dl) 23.9. The majority of patients (n=59, 69%) presented with polyarticular 
disease (≥5 joints involved). Baseline disease activity was high (mean PASDAS 
score 5.1 and significant within group changes in clinical outcomes were seen (Tight 
control group, mean change in PASDAS score 2.2, p < 0.0001; Standard care: 1.1, p 
= 0.03) but between group differences were not significant (F = 3.6, p = 0.06). In the 
imaging sub-studies paired observations (baseline and 48 weeks) were available for 
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61 participants for the MRI and 78 participants for the US groups, with complete 
paired MRI, US and clinical data for 50 participants. The demographics of each of 
these groups (MRI, US and matched) were very similar (see online Supplementary 
table).
MRI results
Inter-observer intra-class correlation for paired observations varied by feature: ICC 
scores (95% confidence intervals) for synovitis 0.85 (0.74 – 0.91), flexor 
tenosynovitis 0.73 (0.54 – 0.85), periarticular inflammation 0.82 (0.69 – .89), bone 
oedema 0.76 (0.59 – 0.86), bone erosion 0.86 (0.76 – 0.92) and bone proliferation 
0.25 (0.30 – 0.57). The data for both readers was combined and expressed as the 
mean. The results for the MRI scores, for each joint level, at each time point, and 
each treatment group are given in Table 1. At the MCP joint a significant difference 
between baseline and 48 weeks was seen in the TC arm for synovitis, flexor 
tenosynovitis, periarticular inflammation, bone oedema and global inflammation but 
not for bone erosion and bone proliferation Comparable changes were seen in the 
StdC arm of the study. At the PIP joint the changes were similar with the exception of 
bone oedema. At the distal inter-phalangeal joint, the differences were less 
pronounced, with only flexor tenosynovitis and global inflammation for both arms of 
the study significantly different between baseline and follow up. SRMs varied from 
0.70 (periarticular inflammation at the MCP joint in the TC arm), to – 0.39 (erosions 
at the DIP joint in the TC arm) and were generally larger for the TC arm. Analysis of 
covariance for individual components of the score (synovitis, tenosynovitis, peri-
articular inflammation, bone oedema, global inflammation, bone erosion and bone 
proliferation) at each joint level, did not show any difference between the two 
treatment groups at 48 weeks for any of the comparisons (statistics not shown).
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Ultrasound results
The results for the US examination at each time point, and each treatment group, for 
McP and PiP joints, are given in Table 2. For approximately two thirds of cases 
inflammation (synovitis) was represented by a GS score of ≥ 2. A significant 
difference was seen for the inflammation score between baseline and 48 weeks for 
both treatment groups. However, there was no difference in scores between 
treatment groups at 48 weeks (F = 0.38, p = 0.75). For erosions, scores were low 
(median of 0 for both groups at baseline and 48 weeks) and no significant 
differences within or between groups were seen at joint or aggregate level.
Relationship between MRI and US data and clinical outcomes
MRI and US scores at baseline, and their change scores, were highly significantly 
correlated (Table 3). A significant correlation was found between baseline PASDAS 
scores and MRI global inflammation scores from the MCP and PIP joint regions 
(Spearman’s rho for MCP, PIP and DIP joint inflammation and PASDAS were 0.46, 
0.63 and 0.35 respectively). However, a non-significant positive correlation was 
found between baseline US inflammation and baseline PASDAS score. Non-
significant positive correlations were found between the change in PASDAS score 
from baseline to week 48 and the change in global inflammation MRI score over the 
same time period.  A significant positive correlation was found between the change 
in PASDAS score from baseline to week 48 and the change in US ‘inflammation’ 
score (rho = 0.37, p = 0.02).
Discussion
 In this sub-study of the TICOPA trial, the individual low-field MRI inflammation 
scores reflected a modest degree of inflammation but consistent with another report 
using the PsAMRIS scoring method in PsA [11]. Although a within-group 
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improvement in the inflammation components of the PsAMRIS score was 
demonstrated for the TC group, the improvements were modest overall, as reflected 
by the standardised response mean, but larger than those seen in the StdC group. 
However, the ‘whole body’ clinical improvements were reflected in the single hand 
MR improvement scores, thus indicating construct validity of the change scores. It is 
also worth noting that the MRI scans in this analysis were low-field scans where 
there are limitations to the images, such as low resolution and difficulty visualising 
the distal inter-phalangeal joints, and there was lack of contrast agent to help define 
inflammation. The relatively oligoarticular nature of PsA, where individual joints may 
be affected in an asymmetrical distribution, compared to RA which is more 
symmetrical and polyarticular, should also be recognised [12]. In this situation 
imaging may show large changes in individual joints but, collectively, over the whole 
hand, the magnitude of change may be smaller when compared to polyarticular 
disease. 
US inflammation scores improved in both treatment groups, and there was a 
significant association between baseline and change in US score and the equivalent 
clinical scores. In this study, therefore, both US and MRI were responsive, aligned 
with baseline clinical scores, and in the case of US, aligned with change in clinical 
scores. It should be noted that MRI and US assessed slightly different joint sets.
In all the imaging/clinical comparisons made in this study, it must be remembered 
that the imaging focussed on the peripheral joints of a single hand, whereas the 
clinical score is more comprehensive, with both patient reported measures, joint 
counts, measures of dactylitis and enthesitis and an acute phase reactant. Although 
the PASDAS response has been shown to correlate with radiographic progression 
scores [13], in this study the use of treatments without proven disease modifying 
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abilities, such as methotrexate, could lower the effect size and interfere with attempts 
to demonstrate relationships between clinical course and imaging changes, and the 
TICOPA study was not powered to demonstrate this. It is also worth noting that the 
design of the TICOPA study does not allow direct comparison of drug efficacy 
between conventional synthetic DMARDs and biologic drugs.
The TICOPA study demonstrated improved clinical outcomes using a treat-to-target 
approach in early PsA but there were no differences in X-ray progression between 
groups. In the current analysis, a sub-study of TICOPA, there were similar within-
group improvements in clinical outcomes but a significant change in most of the 
inflammatory components of an extremity MRI score in the tight control group over 
the 48-week study, and a significant improvement in US inflammation scores in both 
groups. A significant difference between the treatment groups for the change in 
clinical scores was not found in this sub-study, and the imaging modalities also did 
not demonstrate a between-group difference. It must be remembered that both 
groups received active treatment for 48 weeks, there being no placebo group in this 
study. Good correlation between baseline and change scores for MRI and US was 
found, and good correlation between baseline MRI imaging and clinical scores. 
Overall, few erosions were seen and there was little progression over 48 weeks in 
either group.
MRI assesses a greater range of pathologies compared to US yet more recent US 
machines can now give much better detail compared to those used in this paper. 
Future studies of this kind using US could include an assessment of enthesitis and 
tenosynovitis, which may improve responsiveness of a more ‘global’ inflammation 
construct. In this context, dactylitis reflects many of the pathologies seen in PsA, 
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including synovitis, enthesitis and tenosynovitis, but reliable US assessments of 
dactylitis have not yet been developed [14].
The limitations of this study relate to both the modalities and the clinical context. This 
substudy was not powered to show a significant difference in imaging outcomes 
between two active therapies. Secondly, as noted above, the clinical composite used 
relates to total disease burden yet the imaging was confined to a single hand. It may 
be that more extensive joint assessment, such as obtained with total body MR, are 
more closely related to clinical scores such as the PASDAS. Thirdly, the MR 
technique, being a peripheral scanner without the use of contrast, will have limited 
ability to demonstrate improvement in inflammation in any tissue. 
In conclusion, the imaging substudy of TICOPA reported in this paper provides 
further validation for the use of both imaging modalities as outcome measures in this 
disease. The somewhat sporadic joint involvement of PsA, where only a few 
individual joints may be affected, makes aggregate imaging scores less responsive 
to change and future imaging studies should perhaps focus on polyarticular disease 
inclusion, or one manifestation, such as dactylitis, to demonstrate within and 
between group changes in response to treatment. 
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Table 1. MRI scores for each PsAMRIS feature at each joint level, for each treatment group at each time point. 
(a) Metacarpophalangeal joint
Tight control n=31 Standard Care n=30
Score 
Baseline 48 weeks
SRM
z p
Baseline 48 weeks
SRM
z p
Synovitis score 1.5 (0 – 7.5) 0.75 (0 – 2.5)
0.55
2.9 0.003 1.5 (0 – 6.0)
1.0 (0 – 
4.5)
0.44
2.1 0.037
Flexor tenosynovitis 
score
3.0 (0 – 6.0) 1.5 (0 – 4.5)
0.39
2.3 0.020 3.0 (0 – 4.5)
2.25 (0 – 
5.0)
0.29
1.3 ns
Periarticular 
inflammation score
0.5 (0 – 5.5) 0 (0 – 3.5)
0.70
3.2 0.001 0.5 (0 – 5.0) 0 (0 – 2.0)
0.48
2.4 0.016
Bone oedema score 0 (0 – 8.5) 0 (0 – 3.5) 0.35 2.4 0.016 0 (0 – 9.5) 0 (0 – 0) 0.20 1.3 ns
Global inflammation 
score
6.0 (1.0 – 
22.5)
2.5 (0 – 10.5)
0.68
3.3 0.001
5.5 (0 – 
20.0)
3.5 (0 – 
8.5)
0.45
2.1 0.04
Bone erosion score 0 (0 – 12.0) 0 (0 – 11.5) 0.02 0.7 ns 0 (0 – 4.5) 0 (0 – 6.5) 0.30 0.7 ns
Bone proliferation score 0 (0 – 2.5) 0 (0 – 0.5) 0.19 1.4 ns 0 (0 – 0.5) 0 (0 – 0.5) -0.23 1.0 ns
Figures are median (range). n paired ranks test statistic. SRM: standardised response mean. 
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(b) Proximal inter-phalangeal joint
Tight control n=31 Standard Care n=30
Score
Baseline 48 weeks
SRM z p
Baseline 48 weeks
SRM z p
Synovitis score 1.5 (0 – 8.5) 0.5 (0 – 8.0)
0.61
2.8
0.00
6
1.0 (0 – 5.0) 0.5 (0 – 4.0)
0.29
0.9 ns
Flexor tenosynovitis 
score
3.0 (0 – 5.5) 2.0 (0 – 6.0)
0.53
2.5
0.01
4
3.0 (0 – 5.0)
2.25 (0 – 
4.5)
0.29
1.3 ns
Periarticular inflammation 
score
1.0 (0 – 7.5) 0 (0 – 4.0)
0.68
3.4
0.00
1
0.5 (0 – 5.0) 0 (0 – 1.5)
0.67
2.9 0.004
Bone oedema score 0 (0 – 10.0) 0 (0 – 10.0) -0.05 0.2 ns 0 (0 – 6.5) 0 (0 – 4.0) 0.04 0.4 ns
Global inflammation 
score
4.75 (1.5 – 
24.0)
3.5 (0 – 
27.0)
0.55
2.5
0.01
1
4.0 (0 – 
16.0)
3.0 (0 – 
10.0)
0.32
1.7 ns
Bone erosion score 0 (0 – 6.0) 0 (0 – 15.0)
0.04
0.9 ns 0 (0 – 3.0) 0 (0 – 1.5)
-0.19 0.4
0
ns
Bone proliferation score 0 (0 – 2.5) 0 (0 – 3.0) 0.26 0.7 ns 0 (0 – 2.0) 0 (0 – 2.5) 0.05 0.8 ns
Figures are median (range). n paired ranks test statistic. SRM: standardised response mean.
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(c) Distal inter-phalangeal joint
Tight control n=31 Standard Care n=30
Score
Baseline 48 weeks
SRM z P
Baseline 48 weeks
SRM z p
Synovitis score 0.25 (0 – 3.0) 0 (0 – 1.5) 0.42 1.8 Ns 0 (0 – 3.0) 0 (0 – 3.0) 0.09 0.6 ns
Flexor tenosynovitis 
score
1.5 (0 – 3.5) 0 (0 – 4.0)
0.70
2.4 0.015 1.0 (0 – 3.5) 0 (0 – 2.5)
0.58
2.0 0.04
Periarticular 
inflammation score
0 (0 – 7.5) 0 (0 – 2.0)
0.27
1.2 Ns 0 (0 – 2.0) 0 (0 – 0)
0.40
1.6 ns
Bone oedema score 0 (0 – 5.5) 0 (0 – 2.0) 0.14 0.5 Ns 0 (0 – 1.5) 0 (0 – 0) 0.21 1.0 ns
Global inflammation 
score
2.25 (0 – 19.0) 0 (0 – 6.5)
0.46
2.0 0.05 2.0 (0 – 7.0) 0 (0 – 5.0)
0.57
2.0 0.042
Bone erosion score 0 (0 – 1.0) 0 (0 – 2.5) -0.39 1.6 Ns 0 (0 – 0.5) 0 (0 – 0.5) -0.29 0 ns
Bone proliferation score 0 (0 – 2.5) 0 (0 – 1.5) 0.27 0 Ns 0 (0 – 2.0) 0 (0 – 2.0) 0.04 0.5 ns
Figures are median (range). n paired ranks test statistic. SRM: standardised response mean.
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Table 2. Ultrasound scores for each group at baseline and 48 weeks. Figures are median (range). For TC n = 39, for StdC n = 39.
Figures are median (range). n paired ranks test statistic. SRM: standardised response mean.
*GS score of ≥2 and/or a PD score ≥1 aggregated for both metacarpophalangeal (McP) and proximal interphalangeal (PiP) joints
+Erosion score combined for McP and PiP joints
Tight control Standard Care
Score
Baseline 48 weeks
SRM z p
Baseline 48 weeks
SRM z p
Inflammation 
McP G/S ≥ 2 2 (0  11) 0 (0  11) 0.26 1.6 ns 2 (0  12) 2 (0  6 ) 0.71 3.7 0.0001
McP PD ≥ 1 0 (0  4) 0 (0  2) 0.41 2.3 0.02 0 (0  5) 0 (0  3) 0.53 3.0 0.003
PiP G/S ≥ 2 0 (0  12) 0 (0  9) 0.36 2.2 0.03 2 (0  11) 0 (0  9) 0.57 3.0 0.002
PiP PD ≥ 1 0 (0  6) 0 (0  2) 0.38 2.2 0.03 0 (0  7) 0 (0  1) 0.42 2.7 0.007          
Inflammation* 4.5 (0  28) 2 (0  16) 0.64 2.5 0.01 5 (0  20) 2 (0  16) 0.95 4.2 0.0001
Erosions
McP 0 (0  1) 0 (0  1) 0.07 -0.5 ns 0 (0  2) 0 (0  1) 0.05 -0.3 ns
PiP 0 (0  3) 0 (0  4) 0.26 -1.3 ns 0 (0  1) 0 (0  3) 0.22 -1.1 ns
Erosion score+ 0 (0  3) 0 (0  4) 0.41 -1.2 ns 0 (0  3) 0 (0  4) 0.33 -0.5 ns
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Table 3. Relationship between MRI and US scores at baseline and difference between scores at 48 weeks. 
Spearman rho correlation coefficients.
US inflammation at baseline US difference between baseline and 48 weeks
MRI global inflammation 
at baseline
rho p MRI global inflammation 
difference between baseline 
rho p
McP 0.54 0.002 McP 0.62 0.001
PiP 0.53 0.003 PiP 0.64 0.001
Combined McP/PiP 0.62 0.001 Combined McP/PiP 0.67 0.001
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Supplementary table. Demographics of patient groups imaged in this study.
Total patient 
group imaged in 
TICOPA    85
US group n = 
78
MR group n = 
61
Matched US and 
MR n = 50
Age, years mean (sd) 45.1 (13.5) 45.9 (13.2) 45.3 (14.1) 44.6 (14.0)
Gender M/F 40/45 37/41 29/32 21/29
Arthritis subgroup 
Oligoarthritis n (%)
Polyarthritis n (%)
26 (31)
59 (69)
26 (33)
52 (67)
18 (30)
43 (70)
14 (28)
36 (72)
Treatment group
Tight control n, %
Standard care n, %
44 (52)
41 (48)
39 (50)
39 (50)
31 (51)
30 (49)
26 (52)
24 (48)
TJC mean (sd) 11.7 (11.2) 10.8 (10.9) 11.6 (10.2) 12.6 (10.8)
SJC mean (sd) 7.3 (6.8) 6.9 (6.8) 7.2 (6.1) 7.1 (5.9)
PASI mean (sd) 2.7 (2.8) 2.6 (2.8) 2.5 (2.9) 2.3 (2.4)
CRP mg/dL mean (sd) 23.9 (39.6) 21.8 (25.7) 25.1 (42.1) 20.4 (29.3)
PASDAS mean (sd) 5.1 (1.4) 5.0 (1.4) 5.2 (1.3) 5.1 (1.2)
Page 22 of 41
For Peer Review
1
TITLE PAGE
Title: Comparing psoriatic arthritis low-field magnetic resonance imaging, ultrasound 
and clinical outcomes: data from the TICOPA trial
Authors: Philip S Helliwell (0000-0002-4155-9105)1, Laura C Coates (0000-0002-
4756-663X)2, Ne Sian Chew3, Giovanni Lettieri1,3, Anna R Moverley4, Jane E 
Freeston (0000-0003-0358-338X)1, Jackie Nam (0000-0003-4944-7922)1, Robin  
Waxman1, Paul Emery (0000-0002-7429-8482)1, Philip G Conaghan (0000-0002-
3478-5665)1
Key Indexing Terms: Psoriatic arthritis, Magnetic Resonance Imaging, Ultrasound, 
Joint inflammation, Joint erosions
Funding
The TICOPA study was supported by Arthritis Research UK (grant no 18825) and 
Pfizer.  This study presents independent research supported by the National Institute 
for Health Research (NIHR) Leeds Biomedical Research Centre (BRC). The views 
expressed are those of the authors and not necessarily those of the NHS, the NIHR 
or the Department of Health and Social Care. 
Departments and institutions:
1 Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 
and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust
Page 23 of 41
For Peer Review
2
2 Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal 
Sciences, University of Oxford UK 
3 Bradford Teaching Hospitals Foundation Trust, Bradford, UK
4 York Teaching Hospitals NHS Foundation Trust, Scarborough General Hospital, 
Department of Rheumatology, Woodlands Drive, Scarborough, YO12 6QL
Academic degrees
PS Helliwell, MA, PhD, DM, FRCP, Professor of Clinical Rheumatology
Laura C Coates, MBChB, MRCP, NIHR Clinician Scientist
Ne Sian Chew, MRCP, FRCR, Consultant Musculoskeletal Radiologist
Giovanni Lettieri, MD, Hon Consultant Radiologist, Clinical Research Fellow
Anna R Moverley, MBBS, BSc, FRCP, Consultant Rheumatologist
Jane E Freeston,MA, MD, MRCP, Consultant Rheumatologist and Honorary Clinical 
Associate Professor
Jackie Nam, MBBCh FCP, PhD, Consultant in Rheumatology and Honorary Lecturer
Robin Waxman, MPH, Research coordinator
Paul Emery, MA, MD, FRCP, FMedSci, Arthritis Research UK Professor of 
Rheumatology
Philip G Conaghan, MBBS, PhD, FRCP, FRACP, Professor of Musculoskeletal 
Medicine
Corresponding author:
Dr Philip Helliwell
LIRMM 
Chapel Allerton Hospital
Page 24 of 41
For Peer Review
3
Chapeltown Road
Leeds LS7 4SA
UK
Tel: +44 (0)113 392 3064 Fax: +44 (0)113 392 4991
Email: p.helliwell@leeds.ac.uk
Running title: Multi-modality imaging in TICOPA 
Word Count: 274369
Number of Tables: 3
Number of supplementary tables: 0
Number of Figures: 0
Number of appendices: 0
Page 25 of 41
For Peer Review
4
Abstract 
Objective
The Tight Control of Psoriatic arthritis (TICOPA, ISCRCTN30147736) trial, compared 
standard care (StdC) and tight control (TC) in early PsA, demonstrating better 
outcomes for TC. This sub-study evaluated the performance metrics of modern 
imaging outcomes and compared them to the clinical data.
Methods
Non-contrast 0.2TMRI (single hand) was assessed using the OMERACT PsAMRIS 
with an additional global inflammation score. Ultrasound (US, same hand) was 
scored for grey scale, power Doppler and erosions at the metacarpophalangeal 
(MCP) and proximal interphalangeal (PIP) joints and scores summated. 
Results
78 patients had paired (baseline and 48 weeks) US data and 63 paired MRI data; 50 
had matched clinical, MR and US data. Significant within-group changes were seen 
for the inflammatory PsAMRIS components at MCP level: MRI global inflammation 
(Median difference (range), Standardised Response Mean, SRM): 3.25 (- 5.0 – 12.0) 
0.68, 1.0 (-4.5 – 17.5), 0.45 for TC and StdC respectively. Similar within group 
differences were obtained for US: 1.0 (-13.0 – 23.0), 0.45, 3.0 (-6.0 – 21.0), 0.77 for 
TC and StdC respectively. No differences were seen between treatment groups. 
Significant correlations were found between baseline and change MRI and US 
scores. A significant correlation was found between baseline PsA disease activity 
scores and MRI global inflammation scores (Spearman’s rho for MCP, PIP 0.46, 
0.63 respectively). No differences in erosion progression were observed.
Conclusion
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The PsAMRIS and US inflammation scores demonstrated good responsiveness. No 
between group differences were demonstrated but this sub-study was likely under-
powered to determine differences between the two treatment strategies.
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Introduction
The emphasis placed on treating inflammatory arthritis as early as possible to 
minimise damage and functional disability has been shown to be effective in 
rheumatoid arthritis (RA)[1] and the concept has been extended to other 
inflammatory arthritides such as psoriatic arthritis (PsA). The Tight Control of 
inflammation in Psoriatic arthritis (TICOPA) trial targeted early, treatment naïve 
patients and demonstrated improved clinical outcomes above usual care, but was 
unable to demonstrate an advantage in terms of radiographic progression in hands 
and feet [2]. 
Modern imaging modalities such as magnetic resonance imaging (MRI) or 
ultrasound (US) provide sensitive tools to explore both objective inflammation and 
damage responses, though there are extremely few PsA studies using these 
modalities [3].  It is also unclear, given the known patterns of PsA joint involvement, 
whether imaging a single hand (as is typically done in RA trials using MRI) will 
provide a responsive tool. 
The aim of this study was therefore to describe and compare the performance 
metrics of commonly-used MRI and US scores in an imaging sub-study of the 
TICOPA study, and to compare these imaging outcomes with the clinical data 
obtained in this randomised trial.
Patients and Methods
The full trial protocol and clinical results of the TICOPA study have been previously 
reported (ISCRCTN30147736) [2, 4]. In brief this randomised, controlled, parallel 
group, open label, multi-centre clinical trial recruited people with early (less than 2 
years), treatment naive PsA. The trial had ethical approval from North East York 
Ethics Committee (14/NE/1090) and all participants gave written informed consent.  
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The primary objective of the main trial was to compare tight control (TC) with 
standard care (StdC), using minimal disease activity (MDA[5]) as the treatment 
target. Participants received either TC or StdC for a period of 48 weeks. Participants 
randomised to TC were seen every 4 weeks by the study physician and treated 
according to a predefined treatment protocol.  Participants randomised to the StdC 
arm were treated in a general rheumatology outpatient clinic supervised by a 
consultant rheumatologist.  These patients were generally reviewed every 12 weeks 
but were seen more often if clinically indicated, with no formal measures of disease 
activity used in clinical decision making. A blinded assessor collected clinical 
assessments and patient reported outcomes every 12 weeks. Disease activity was 
measured using the Psoriatic arthritis Disease Activity Score (PASDAS) which 
assesses patient and physician global assessment of disease, tender and swollen 
joint counts, dactylitis and enthesitis, CRP and the physical summary subscale of the 
short form 36 health related quality of life [6]. 
Magnetic Resonance Imaging
At the Leeds site, consenting patients were invited to participate in both MRI and US 
sub-studies, imaging the hand (the most affected hand, or the dominant hand if both 
were asymptomatic). Imaging was performed with both a non-contrast low field 
extremity MRI (0.2T C-scan, Esaote, Genova, Italy) and an US scan at baseline and 
48 weeks. 
MRI imaging
For the MRI scan the imaging sequences and details of scoring are as follow:
Scout. Whole hand FOV 140*140 TR 140ms. Matrix 192*128
STIR coronal. TR 2620ms. 160*160 matrix 192*144. 3 slices. 24 echoes.
STIR sagittal. TR 2840ms. 190*190. 192*144. 4 slices. 25 echoes.
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T1 3D coronal. T3D T1. TR 35ms. 140*140 80 matrix 192*160 72. 2 slices 88 
echoes. 
Images were scored for the second to fifth fingers at each level in the hand 
(metacarpophalangeal joint, proximal interphalangeal joint, distal interphalangeal joint) 
for the following features based on the OMERACT PsAMRIS score [7].:
Synovitis: Grading scale: 0 is normal, while 1–3 is mild, moderate, severe, by thirds 
of the maximum potential volume of tissue. Score range at each level for eachfinger, 
0 – 36.
Tenosynovitis: Grading scale: the maximal thickness of  signal as follows: 0:
none; 1: < 1/2 tendon thickness; 2: ≥ 1/2 and < 1 tendon
thickness; 3: ≥ 1 tendon thickness. Score range at each level for each finger, 0 – 36.
Periarticular inflammation (distal and proximal):  Grading scale, 0 absent, 1 present 
on both dorsal and volar aspects. Score range at each level for each finger, 0 – 24.
Bone edema (distal and proximal):  Grading scale: the scale is based on the 
proportion of bone with edema, compared to the assessed bone volume, judged 
on all available images: 0: no edema; 1: 1–33% of bone edematous; 2: 34–66%; 3:
67–100% scored on either side of the joint. Score range at each level for each finger, 
0 – 72.
Scores for synovitis, tenosynovitis, peri-articular inflammation and bone oedema 
were summed to give a ‘global inflammation’ score at each level, for each finger, 
score range 0 – 168. The aggregate scores at each level were retained in order to 
examine the responsiveness of ‘global inflammation’ in very small joints such as the 
DIPJ, and to determine which joints demonstrated most change with respect to this 
feature.
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Bone erosion (distal and proximal): Grading scale: the scale is 0–10, based on the 
proportion of eroded bone compared to the assessed bone volume, judged on 
all available images: 0:no erosion; 1: 1–10% of bone eroded; 2: 11–20%, and so on. 
Scored at either side of the joint. Score range at each level for all 4 fingers 0 – 240.
Bone proliferation: Grading scale: 0 absent, 1 present. Score range at each level for 
all 4 fingers 0 – 12.
 The images were read by two independent readers (NC, GL), anonymized to patient 
demographics, treatment group and time order. Inter-rater reliability for domain 
scores at each joint level was calculated by intra-class correlation coefficients.
Ultrasound imaging 
One of two ultrasonographers (JF and JN) scanned the same hand as the MRI using 
a Philips HDI 5000 (Best, The Netherlands) machine employing 12-5 and 15-7 MHz 
linear transducers and were unaware of the clinical examination findings. The inter-
rater agreement between these assessors for this group of patients has been 
previously reported [8].   PD was assessed using a pulse repetition frequency of 750 
Hz and medium wall filter and gain was adjusted until background signal was 
removed.  Each joint was scanned in both longitudinal and transverse planes from 
the dorsal aspect. For the small joints of the hand the second to fifth 
metacarpophalangeal (MCP) joints, and the second to fifth proximal inter-phalangeal 
(PIP) joints were examined. GS and PD were scored separately on a 0-3 semi-
quantitative scale for each joint imaged.  A GS score of ≥2 and/or a PD score ≥1 
were used to identify US active joints. The GS and PD scores were summated to 
give an overall score for ‘inflammation’ (total possible score of 48) [9]. Erosions were 
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defined as a definite cortical break seen in two planes and scored as present or 
absent at the joint level, so the maximum score for erosions per hand was 8. 
Statistical analysis
The original TICOPA study was appropriately powered for its clinical outcome, but no 
formal power calculation was made for this sub-study. Only matched (baseline and 
follow up) MRI and US data, and combined MRI, US and clinical data were used. 
There was no data imputation. The clinical composite outcome (the Psoriatic arthritis 
Disease Activity Index, PASDAS), was derived as previously described [6]. 
Significance was assumed at a level of 5%; no correction was made for multiple 
comparisons. Inter-rater reliability for aggregate MR scores was assessed using the 
intra-class correlation coefficient. The magnitude of MR parameter response was 
compared using the standardised response mean (SRM), calculated as the mean 
difference between time points divided by the standard deviation of the difference 
[10]. Statistical testing was carried out using SPSS v21.
Results
In the TICOPA study 206 patients were recruited and of these 85 entered imaging 
sub-studies. Clinical characteristics of the patients in this study were: Male/Female 
40/45; mean age 45.1 years; mean tender joint count 11.7; mean swollen joint count 
7.3; mean skin score (Psoriasis Area and Severity Score: PASI) 2.7; mean CRP 
(mg/dl) 23.9. The majority of patients (n=59, 69%) presented with polyarticular 
disease (≥5 joints involved). Baseline disease activity was high (mean PASDAS 
score 5.1 and significant within group changes in clinical outcomes were seen (Tight 
control group, mean change in PASDAS score 2.2, p < 0.0001; Standard care: 1.1, p 
= 0.03) but between group differences were not significant (F = 3.6, p = 0.06). In the 
imaging sub-studies paired observations (baseline and 48 weeks) were available for 
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61 participants for the MRI and 78 participants for the US groups, with complete 
paired MRI, US and clinical data for 50 participants. The demographics of each of 
these groups (MRI, US and matched) were very similar (see online Supplementary 
table).
MRI results
Inter-observer intra-class correlation for paired observations varied by feature: ICC 
scores (95% confidence intervals) for synovitis 0.85 (0.74 – 0.91), flexor 
tenosynovitis 0.73 (0.54 – 0.85), periarticular inflammation 0.82 (0.69 – .89), bone 
oedema 0.76 (0.59 – 0.86), bone erosion 0.86 (0.76 – 0.92) and bone proliferation 
0.25 (0.30 – 0.57). The data for both readers was combined and expressed as the 
mean. The results for the MRI scores, for each joint level, at each time point, and 
each treatment group are given in Table 1. At the MCP joint a significant difference 
between baseline and 48 weeks was seen in the TC arm for synovitis, flexor 
tenosynovitis, periarticular inflammation, bone oedema and global inflammation but 
not for bone erosion and bone proliferation Comparable changes were seen in the 
StdC arm of the study. At the PIP joint the changes were similar with the exception of 
bone oedema. At the distal inter-phalangeal joint, the differences were less 
pronounced, with only flexor tenosynovitis and global inflammation for both arms of 
the study significantly different between baseline and follow up. SRMs varied from 
0.70 (periarticular inflammation at the MCP joint in the TC arm), to – 0.39 (erosions 
at the DIP joint in the TC arm) and were generally larger for the TC arm. Analysis of 
covariance for individual components of the score (synovitis, tenosynovitis, peri-
articular inflammation, bone oedema, global inflammation, bone erosion and bone 
proliferation) at each joint level, did not show any difference between the two 
treatment groups at 48 weeks for any of the comparisons (statistics not shown).
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Ultrasound results
The results for the US examination at each time point, and each treatment group, for 
McP and PiP joints, are given in Table 2. For approximately two thirds of cases 
inflammation (synovitis) was represented by a GS score of ≥ 2. A significant 
difference was seen for the inflammation score between baseline and 48 weeks for 
both treatment groups. However, there was no difference in scores between 
treatment groups at 48 weeks (F = 0.38, p = 0.75 ). For erosions, scores were low 
(median of 0 for both groups at baseline and 48 weeks) and no significant 
differences within or between groups were seen at joint or aggregate level.
Relationship between MRI and US data and clinical outcomes
MRI and US scores at baseline, and their change scores, were highly significantly 
correlated (Table 3). A significant correlation was found between baseline PASDAS 
scores and MRI global inflammation scores from the MCP and PIP joint regions 
(Spearman’s rho for MCP, PIP and DIP joint inflammation and PASDAS were 0.46, 
0.63 and 0.35 respectively). However, a non-significant positive correlation was 
found between baseline US inflammation and baseline PASDAS score. Non-
significant positive correlations were found between the change in PASDAS score 
from baseline to week 48 and the change in global inflammation MRI score over the 
same time period.  A significant positive correlation was found between the change 
in PASDAS score from baseline to week 48 and the change in US ‘inflammation’ 
score (rho = 0.37, p = 0.02).
Discussion
 In this sub-study of the TICOPA trial, the individual low-field MRI inflammation 
scores reflected a modest degree of inflammation but consistent with another report 
using the PsAMRIS scoring method in PsA [11]. Although a within-group 
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improvement in the inflammation components of the PsAMRIS score was 
demonstrated for the TC group, the improvements were modest overall, as reflected 
by the standardised response mean, but larger than those seen in the StdC group. 
However, the ‘whole body’ clinical improvements were reflected in the single hand 
MR improvement scores, thus indicating construct validity of the change scores. It is 
also worth noting that the MRI scans in this analysis were low-field scans where 
there are limitations to the images, such as low resolution and difficulty visualising 
the distal inter-phalangeal joints, and there was lack of contrast agent to help define 
inflammation. The relatively oligoarticular nature of PsA, where individual joints may 
be affected in an asymmetrical distribution, compared to RA which is more 
symmetrical and polyarticular, should also be recognised [12]. In this situation 
imaging may show large changes in individual joints but, collectively, over the whole 
hand, the magnitude of change may be smaller when compared to polyarticular 
disease. 
US inflammation scores improved in both treatment groups, and there was a 
significant association between baseline and change in US score and the equivalent 
clinical scores. In this study, therefore, both US and MRI were responsive, aligned 
with baseline clinical scores, and in the case of US, aligned with change in clinical 
scores. It should be noted that MRI and US assessed slightly different joint sets.
In all the imaging/clinical comparisons made in this study, it must be remembered 
that the imaging focussed on the peripheral joints of a single hand, whereas the 
clinical score is more comprehensive, with both patient reported measures, joint 
counts, measures of dactylitis and enthesitis and an acute phase reactant. Although 
the PASDAS response has been shown to correlate with radiographic progression 
scores [13], in this study the use of treatments without proven disease modifying 
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abilities, such as methotrexate, could lower the effect size and interfere with attempts 
to demonstrate relationships between clinical course and imaging changes, and the 
TICOPA study was not powered to demonstrate this. It is also worth noting that the 
design of the TICOPA study does not allow direct comparison of drug efficacy 
between conventional synthetic DMARDs and biologic drugs.
The TICOPA study demonstrated improved clinical outcomes using a treat-to-target 
approach in early PsA but there were no differences in X-ray progression between 
groups. In the current analysis, a sub-study of TICOPA, there were similar within-
group improvements in clinical outcomes but a significant change in most of the 
inflammatory components of an extremity MRI score in the tight control group over 
the 48-week study, and a significant improvement in US inflammation scores in both 
groups. A significant difference between the treatment groups for the change in 
clinical scores was not found in this sub-study, and the imaging modalities also did 
not demonstrate a between-group difference. It must be remembered that both 
groups received active treatment for 48 weeks, there being no placebo group in this 
study. Good correlation between baseline and change scores for MRI and US was 
found, and good correlation between baseline MRI imaging and clinical scores. 
Overall, few erosions were seen and there was little progression over 48 weeks in 
either group.
MRI assesses a greater range of pathologies compared to US yet more recent US 
machines can now give much better detail compared to those used in this paper. 
Future studies of this kind using US could include an assessment of enthesitis and 
tenosynovitis, which may improve responsiveness of a more ‘global’ inflammation 
construct. In this context, dactylitis reflects many of the pathologies seen in PsA, 
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including synovitis, enthesitis and tenosynovitis, but reliable US assessments of 
dactylitis have not yet been developed [14].
The limitations of this study relate to both the modalities and the clinical context. This 
substudy was not powered to show a significant difference in imaging outcomes 
between two active therapies. Secondly, as noted above, the clinical composite used 
relates to total disease burden yet the imaging was confined to a single hand. It may 
be that more extensive joint assessment, such as obtained with total body MR, are 
more closely related to clinical scores such as the PASDAS. Thirdly, the MR 
technique, being a peripheral scanner without the use of contrast, will have limited 
ability to demonstrate improvement in inflammation in any tissue. 
In conclusion, the imaging substudy of TICOPA reported in this paper provides 
further validation for the use of both imaging modalities as outcome measures in this 
disease. The somewhat sporadic joint involvement of PsA, where only a few 
individual joints may be affected, makes aggregate imaging scores less responsive 
to change and future imaging studies should perhaps focus on polyarticular disease 
inclusion, or one manifestation, such as dactylitis, to demonstrate within and 
between group changes in response to treatment. 
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Table 2. Ultrasound scores for each group at baseline and 48 weeks. Figures are median (range). For TC n = 39, for StdC n = 39.
Figures are median (range). n paired ranks test statistic. SRM: standardised response mean.
*GS score of ≥2 and/or a PD score ≥1 aggregated for both metacarpophalangeal (McP) and proximal interphalangeal (PiP) joints
+Erosion score combined for both McP and PiP joints
Tight control Standard Care
Score
Baseline 48 weeks
SRM z p
Baseline 48 weeks
SRM z p
Inflammation* 4.5 (0  28) 2 (0  16) 0.64 2.5 0.01 5 (0  20) 2 (0  16) 0.95 4.2 0.0001
Inflammation 
McP G/S ≥ 2 2 (0  11) 0 (0  11) 0.26 1.6 ns 2 (0  12) 2 (0  6 ) 0.71 3.7 0.0001
McP PD ≥ 1 0 (0  4) 0 (0  2) 0.41 2.3 0.02 0 (0  5) 0 (0  3) 0.53 3.0 0.003
PiP G/S ≥ 2 0 (0  12) 0 (0  9) 0.36 2.2 0.03 2 (0  11) 0 (0  9) 0.57 3.0 0.002
PiP PD ≥ 1 0 (0  6) 0 (0  2) 0.38 2.2 0.03 0 (0  7) 0 (0  1) 0.42 2.7 0.007          
Inflammation* 4.5 (0  28) 2 (0  16) 0.64 2.5 0.01 5 (0  20) 2 (0  16) 0.95 4.2 0.0001
Erosions
McP 0 (0  1) 0 (0  1) 0.07 -0.5 ns 0 (0  2) 0 (0  1) 0.05 -0.3 ns
PiP 0 (0  3) 0 (0  4) 0.26 -1.3 ns 0 (0  1) 0 (0  3) 0.22 -1.1 ns
Erosion score+ 0 (0  3) 0 (0  4) -0.41 -1.2 ns 0 (0  3) 0 (0  4) -0.33 -0.5 ns
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